药品注册申请号:050558
申请类型:NDA (新药申请)
申请人:PAI HOLDINGS PHARM
申请人全名:PAI HOLDINGS LLC DBA PHARMACEUTICAL ASSOCIATES INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
002 ZINACEF CEFUROXIME SODIUM INJECTABLE;INTRAMUSCULAR, INTRAVENOUS EQ 750MG BASE/VIAL Yes No AB 1983/10/19 1983/10/19 Discontinued
003 ZINACEF CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 1.5GM BASE/VIAL Yes No AP 1983/10/19 Discontinued
004 ZINACEF CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 7.5GM BASE/VIAL Yes No AP 1986/10/23 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2021/05/16 SUPPL-76(补充) Approval Labeling STANDARD
2020/02/11 SUPPL-75(补充) Approval Labeling STANDARD
2015/03/16 SUPPL-73(补充) Approval Manufacturing (CMC) STANDARD
2014/09/25 SUPPL-69(补充) Approval Labeling STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
2013/08/14 SUPPL-72(补充) Approval Manufacturing (CMC) STANDARD
2007/07/30 SUPPL-67(补充) Approval Labeling STANDARD
2004/05/19 SUPPL-57(补充) Approval Labeling STANDARD
2002/10/23 SUPPL-54(补充) Approval Manufacturing (CMC) STANDARD
2001/11/09 SUPPL-53(补充) Approval Manufacturing (CMC) STANDARD
2001/10/12 SUPPL-50(补充) Approval Labeling STANDARD
2001/07/12 SUPPL-49(补充) Approval Labeling STANDARD
2001/05/05 SUPPL-52(补充) Approval Manufacturing (CMC) STANDARD
2001/04/13 SUPPL-51(补充) Approval Manufacturing (CMC) STANDARD
1997/04/03 SUPPL-48(补充) Approval Manufacturing (CMC) STANDARD
1996/12/23 SUPPL-47(补充) Approval Labeling STANDARD
1996/12/23 SUPPL-44(补充) Approval Labeling STANDARD
1996/09/11 SUPPL-45(补充) Approval Labeling STANDARD
1995/10/31 SUPPL-46(补充) Approval Manufacturing (CMC) STANDARD
1995/10/23 SUPPL-31(补充) Approval Labeling
1995/09/29 SUPPL-43(补充) Approval Labeling STANDARD
1995/02/06 SUPPL-37(补充) Approval Labeling STANDARD
1994/10/27 SUPPL-41(补充) Approval Labeling STANDARD
1993/06/28 SUPPL-42(补充) Approval Manufacturing (CMC) STANDARD
1993/02/18 SUPPL-36(补充) Approval Manufacturing (CMC) STANDARD
1992/12/31 SUPPL-40(补充) Approval Labeling
1992/11/04 SUPPL-30(补充) Approval Manufacturing (CMC) STANDARD
1992/09/23 SUPPL-35(补充) Approval Manufacturing (CMC) STANDARD
1992/02/13 SUPPL-32(补充) Approval Manufacturing (CMC) STANDARD
1992/02/13 SUPPL-29(补充) Approval Manufacturing (CMC) STANDARD
1992/02/13 SUPPL-28(补充) Approval Manufacturing (CMC) STANDARD
1991/08/14 SUPPL-33(补充) Approval Manufacturing (CMC) STANDARD
1990/03/22 SUPPL-27(补充) Approval Manufacturing (CMC) STANDARD
1989/06/30 SUPPL-26(补充) Approval Labeling
1989/03/24 SUPPL-25(补充) Approval Manufacturing (CMC) STANDARD
1988/05/12 SUPPL-20(补充) Approval Labeling
1987/09/25 SUPPL-24(补充) Approval Manufacturing (CMC) STANDARD
1987/08/28 SUPPL-23(补充) Approval Labeling
1987/08/13 SUPPL-22(补充) Approval Manufacturing (CMC) STANDARD
1986/10/23 SUPPL-19(补充) Approval Labeling
1986/05/30 SUPPL-18(补充) Approval Manufacturing (CMC) STANDARD
1986/04/17 SUPPL-17(补充) Approval Manufacturing (CMC) STANDARD
1986/01/23 SUPPL-15(补充) Approval Manufacturing (CMC) STANDARD
1985/11/25 SUPPL-13(补充) Approval Manufacturing (CMC) STANDARD
1985/04/03 SUPPL-12(补充) Approval Manufacturing (CMC) STANDARD
1984/08/20 SUPPL-9(补充) Approval Manufacturing (CMC) STANDARD
1984/07/27 SUPPL-10(补充) Approval Manufacturing (CMC) STANDARD
1984/05/11 SUPPL-8(补充) Approval Labeling
1984/04/18 SUPPL-7(补充) Approval Labeling
1984/03/05 SUPPL-6(补充) Approval Labeling
1984/02/17 SUPPL-5(补充) Approval Labeling
1984/02/08 SUPPL-4(补充) Approval Manufacturing (CMC) STANDARD
1983/12/22 SUPPL-2(补充) Approval Labeling
1983/12/07 SUPPL-1(补充) Approval Labeling
1983/10/19 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:CEFUROXIME SODIUM 剂型/给药途径:INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 规格:EQ 750MG BASE/VIAL 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050558 002 NDA ZINACEF CEFUROXIME SODIUM INJECTABLE;INTRAMUSCULAR, INTRAVENOUS EQ 750MG BASE/VIAL Discontinued Yes No AB 1983/10/19 PAI HOLDINGS PHARM
064125 001 ANDA CEFUROXIME SODIUM CEFUROXIME SODIUM INJECTABLE;INTRAMUSCULAR, INTRAVENOUS EQ 750MG BASE/VIAL Prescription No No AB 1997/05/30 ACS DOBFAR SPA
065048 001 ANDA CEFUROXIME SODIUM CEFUROXIME SODIUM INJECTABLE;INTRAMUSCULAR, INTRAVENOUS EQ 750MG BASE/VIAL Prescription No Yes AB 2004/01/09 HIKMA
活性成分:CEFUROXIME SODIUM 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 1.5GM BASE/VIAL 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050558 003 NDA ZINACEF CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 1.5GM BASE/VIAL Discontinued Yes No AP 1983/10/19 PAI HOLDINGS PHARM
064125 002 ANDA CEFUROXIME SODIUM CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 1.5GM BASE/VIAL Prescription No No AP 1997/05/30 ACS DOBFAR SPA
050780 002 NDA CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 1.5GM BASE/VIAL Discontinued Yes No AP 2001/02/21 B BRAUN
065048 002 ANDA CEFUROXIME SODIUM CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 1.5GM BASE/VIAL Prescription No Yes AP 2004/01/09 HIKMA
活性成分:CEFUROXIME SODIUM 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 7.5GM BASE/VIAL 治疗等效代码:AP
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050558 004 NDA ZINACEF CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 7.5GM BASE/VIAL Discontinued Yes No AP 1986/10/23 PAI HOLDINGS PHARM
064124 001 ANDA CEFUROXIME SODIUM CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 7.5GM BASE/VIAL Discontinued No No AP 1997/05/30 ACS DOBFAR SPA
065046 001 ANDA CEFUROXIME SODIUM CEFUROXIME SODIUM INJECTABLE;INJECTION EQ 7.5GM BASE/VIAL Discontinued No No AP 2004/01/09 HIKMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database